Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC10914 (Simmiparib) in gBRCA1/2 mutated advanced ovarian cancer
NCT04556539Phase 2Unknown
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of simmiparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Status: unknown.
02
Drugs
simmiparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04556539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04556539.